Hospital Universitario Virgen Macarena
Seville, Spain
56 recruiting
Showing 1–20 of 83 trials
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Rheumatoid Arthritis
Hoffmann-La Roche160 enrolled46 locationsNCT07137598
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled339 locationsNCT05633654
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Metastatic Breast Cancer
Hoffmann-La Roche230 enrolled192 locationsNCT05894239
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled294 locationsNCT06926868
Recruiting
Phase 3
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Urothelial CarcinomaUpper Urinary Tract Urothelial Carcinoma
UroGen Pharma Ltd.70 enrolled52 locationsNCT06774131
Recruiting
Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled228 locationsNCT06935357
Recruiting
Phase 2
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Breast Cancer
Hoffmann-La Roche60 enrolled30 locationsNCT07054190
Recruiting
Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled317 locationsNCT07174336
Recruiting
Phase 2
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
Hoffmann-La Roche182 enrolled56 locationsNCT07074886
Recruiting
Phase 3
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Bristol-Myers Squibb194 enrolled33 locationsNCT06408259
Recruiting
Not Applicable
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
Breast CancerRadiotherapy Side EffectSentinel Lymph Node+2 more
Hospital Universitari de Bellvitge820 enrolled60 locationsNCT04889924
Recruiting
Phase 2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Progressive Multiple Sclerosis
Hoffmann-La Roche360 enrolled47 locationsNCT07282574
Recruiting
Phase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Clostridium Difficile Infection RecurrenceClostridium DifficileClostridioides Difficile Infection+7 more
Vedanta Biosciences, Inc.852 enrolled215 locationsNCT06237452
Recruiting
Phase 1Phase 2
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Colorectal, CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc.534 enrolled53 locationsNCT06128551
Recruiting
Phase 1Phase 2
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Breast CancerSolid Tumors, Adult
Eli Lilly and Company880 enrolled66 locationsNCT05768139
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Extensive-stage Small-cell Lung Cancer
Bristol-Myers Squibb530 enrolled184 locationsNCT06646276
Recruiting
Phase 2
Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression
Ovarian CancerOligometastatic DiseaseSerous Ovarian Tumor
MedSIR30 enrolled14 locationsNCT06180356
Recruiting
Phase 2
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Ulcerative ColitisUlcerative Colitis Chronic
Eli Lilly and Company140 enrolled207 locationsNCT06598943
Recruiting
Phase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ulcerative ColitisObesity or Overweight
Eli Lilly and Company350 enrolled191 locationsNCT06937086
Recruiting
Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia, B-cell+1 more
Loxo Oncology, Inc.662 enrolled144 locationsNCT05254743